Description | CD16 is low affinity IgG Fc receptor III (FcR III) and CD32 is FcR II. CD16/CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. The Fc receptors bind antibody-antigen immune complexes and mediate adaptive immune responses. |
Recommended Usage | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd. |
References | 1. Personal communication (IP) 2. Oliver AM, et al. 1999. Hybridoma 18:113. (Block) 3. Brummel R and Lenert P. 2005. J. Immunol. 174:2429. 4. Terrazas LI, et al. 2005. Int. J. Parasitol. 35:1349. (Block) 5. Clements JL, et al. 2006. J. Immunol. 177:905. 6. Mohamed W, et al. 2010. Infect Immun. 78:3306. PubMed 7. Ouchi T, et al. 2011. J. Exp Med. 208:2607. PubMed 8. Kmieciak M, et al. 2011. J. Vis. Exp. 47:2381. PubMed 9. Yamazaki S, et al. 2012. PLoS One. 7:e51665. PubMed 10. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed 11. Azuma M, et al. 2012. Oncoimmunology. 1:581. PubMed 12. Koon HW, et al. 2013. J. Vis. Exp. 68:4208. PubMed 13. Hegde VL, et al. 2013. J Biol Chem. 288:36810. PubMed 14. Huang J, et al. 2013. J. Immunol Methods. 387:254. PubMed 15. Dutow P, et al. 2014. J Infect Dis. PubMed 16. Fan Y, et al. 2014. J Exp Med. 211:313. PubMed 17. Huang HN, et al. 2014. Antimicrob Agents Chemother. 58:1538. PubMed 18. Takei S, et al. 2014. Vaccine. 32:3066. PubMed 19. Richardson ML, et al. 2014. PLoS Negl Trop Dis. 8:2825. PubMed 20. Cekanaviciute E, et al. 2014. J Immunol. 193:139. PubMed 21. Kimura T, et al. 2014. Int Immunol. 26:697. PubMed 22. Everad A, et al. 2014. Nat Commun. 5:5648. PubMed 23. Cenci E, et al. 2006. J. Leuko. Biol. 79(1):40-5. (Block) |